- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07668687
European Multi-Centre Post-Market Registry on Thoracic Endovascular Arch Repair Using Castor™ and Cratos™ (CEDAR)
June 23, 2026 updated by: Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd
European Multi-Centre Castor™ and Cratos™ Branched Endovascular Arch Repair Registry
The Castor™ and Cratos™ Branched Aortic Stent Graft Systems are medical devices designed for the minimally invasive endovascular treatment of thoracic aortic pathologies in the descending aorta.
The goal of this multi-centre retrospective and prospective observational registry study is to capture the short-, medium- to long-term safety and performance data of how Castor™ and Cratos™ stent-grafts work in real-world settings (everyday medical practice).
The aim is to study approximately 100 patients in European hospitals, with competitive enrollment.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
The CEDAR registry is a post-market clinical study with retrospective and prospective enrollment and retrospective and prospective data collection.
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Maggie Shen, MD MSc
- Phone Number: 00441235750800
- Email: maggie.shen@endovastec-lm.com
Study Contact Backup
- Name: Anne Woodman
- Phone Number: 00441235750800
- Email: anne.woodman@endovastec-lm.com
Study Locations
-
-
-
Hamburg, Germany, 20099
- Recruiting
- ASKLEPIOS Kliniken St. Georg
-
Contact:
- Prof. Dr. med.
- Phone Number: 2492 004940181885
- Email: t.koeppel@asklepios.com
-
Principal Investigator:
- Thomas A Koeppel, Prof. Dr. med.
-
Sub-Investigator:
- Hans Christian Voigt, Dr. med. univ.
-
Münster, Germany, 48149
- Recruiting
- Universitätsklinikum Münster (UKM)
-
Contact:
- Jana Ebing
- Phone Number: 00492518351717
- Email: vital@ukmuenster.de
-
Principal Investigator:
- Alexander Oberhuber, Dr. med. univ.
-
-
-
-
-
Sion, Switzerland, 1951
- Recruiting
- Hopital de Sion
-
Contact:
- Daniel Danzer
- Phone Number: 0041276034124
- Email: daniel.danzer@hopitalvs.ch
-
Principal Investigator:
- Daniel Danzer
-
Zurich, Switzerland, CH-8091
- Recruiting
- Universitätsspital Zürich (USZ)
-
Contact:
- Susanne Menz
- Phone Number: 0041432530243
- Email: Susanne.Menz@usz.ch
-
Principal Investigator:
- Alexander Zimmermann, Prof. Dr. med.
-
Sub-Investigator:
- Benedikt Reutersberg,, PD Dr. med.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
approximately 100 patients in Europe, competitive enrolment
Description
Inclusion Criteria:
- Implantation of a Castor™ or Cratos™ single branch endoprothesis with incorporation of the left subclavian artery
- Age >18 years
Exclusion Criteria:
- Patients allergic to the materials of the device;
- Patients with severe or potentially systemic infections that increase the chance of graft infection;
- Minors and pregnant women;
- Branch for other supra-aortic vessels than the LSA
- Rejection of participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Cohort 1: patients treated with Castor™
Arch involving aortic pathologies treated with the Castor™ stent graft system.
|
Treatment of subjects diagnosed with thoracic aortic pathologies using the Castor™ Branched Aortic Stent-Graft and Delivery System.
Follow up as per institutional standard of care.
|
|
Cohort 2: patients treated with Cratos™
Arch involving aortic pathologies treated with the Cratos™ stent graft system.
|
Treatment of subjects diagnosed with thoracic aortic pathologies using the Cratos™ Branched Aortic Stent-Graft and Delivery System.
Follow up as per institutional standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
30-day all-cause mortality
Time Frame: 30 days
|
A measure of the total number of patients participating in the CEDAR study who die from any cause within 30 days of the implantation of the branched aortic stent graft - Castor™ or Cratos™.
|
30 days
|
|
Technical success rate
Time Frame: 24 hours
|
Technical Success is defined as successful access and deployment of the endograft, including implantation of the branch into the target vessel, with patency of the branch and no evidence of type I or type III endoleak on completion angiography or cone-beam computed tomography.
Additional intra-operative measures to achieve this, such as ballooning or branch extension with additional stent grafts, are also considered as primary technical success.
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical success rate at 30 days, 6 months and at 1 - 5 years
Time Frame: at 30 days, 6 months and at 1 - 5 years
|
This is defined as Technical Success plus the absence of aortic related death, aortic rupture, graft infection, sac expansion > 5mm, graft migration >10mm, persistent endoleaks type I and III requiring re-intervention, conversion to open surgery, permanent paraplegia, disabling stroke or permanent dialysis.
|
at 30 days, 6 months and at 1 - 5 years
|
|
Rate of Endoleak
Time Frame: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
|
|
Branch occlusion rate
Time Frame: at 30 days, 6 months, and 1-5 year
|
at 30 days, 6 months, and 1-5 year
|
|
|
Rate of perioperative retrograde type A aortic dissections
Time Frame: 30 days, 6 months, and at 1 - 5 years
|
30 days, 6 months, and at 1 - 5 years
|
|
|
Rate of reintervention
Time Frame: at 30 days, 6 months, and at 1-5 years
|
at 30 days, 6 months, and at 1-5 years
|
|
|
Combined endpoint major adverse events
Time Frame: at 30-days, 6 months and 1 year
|
all-cause mortality, myocardial infarction, respiratory failure with postoperative prolonged mechanical ventilation > 24h, renal function declining in a GFR > 50% reduction to perioperative, bowel ischemia requiring surgical resection, major stroke and permanent paraplegia.
|
at 30-days, 6 months and 1 year
|
|
Incidence rate of spinal cord ischemia for the duration of the study
Time Frame: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
|
|
Stroke rate
Time Frame: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
|
|
All-cause mortality
Time Frame: at 30 days, 6 months, and at 1 - 5 years
|
at 30 days, 6 months, and at 1 - 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Jing Wang, Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 12, 2025
Primary Completion (Estimated)
October 1, 2028
Study Completion (Estimated)
December 1, 2033
Study Registration Dates
First Submitted
May 20, 2026
First Submitted That Met QC Criteria
June 23, 2026
First Posted (Actual)
June 25, 2026
Study Record Updates
Last Update Posted (Actual)
June 25, 2026
Last Update Submitted That Met QC Criteria
June 23, 2026
Last Verified
June 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Dissection, Blood Vessel
- Acute Aortic Syndrome
- Vascular Diseases
- Cardiovascular Diseases
- Pathologic Processes
- Hemorrhage
- Arteriosclerosis
- Arterial Occlusive Diseases
- Aortic Diseases
- Aneurysm
- Aortic Dissection
- Pathological Conditions, Signs and Symptoms
- Hematoma
- Penetrating Atherosclerotic Ulcer
- Dissection, Thoracic Aorta
- Aortic Intramural Hematoma
- Aortic Aneurysm
- Aortic Aneurysm, Thoracic
Other Study ID Numbers
- PMCF-2025-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.